0 Yorumlar
0 hisse senetleri
215 Views
0 önizleme
Site içinde arama yapın
Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek
- Please log in to like, share and comment!
- HER-2 Negative Breast Cancer Market Expected to Witness High Growth Owing to Increasing Prevalence of Breast CancerThe HER-2 negative breast cancer market is estimated to be valued at US$ 13,873.7 Mn in 2023 and is expected to exhibit a CAGR of 10.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview:HER-2 negative breast cancer accounts for around 70% of all breast cancer cases globally. It develops in breast cells that lack excess...0 Yorumlar 0 hisse senetleri 1312 Views 0 önizleme
- Hyperthermia Cancer Treatment Is Driven By Increasing Incidences Of CancerHyperthermia Cancer Treatment involves applying heat at the targeted area of the tumor to destroy and kill cancer cells. It works on the principle that heat can be used to damage and kill cancer cells or to make cancer cells more sensitive to the effects of radiation and certain anticancer drugs. During hyperthermia therapy, the region of the body containing the tumor is heated to temperatures...0 Yorumlar 0 hisse senetleri 1054 Views 0 önizleme
- Metastatic Melanoma Therapeutics Market is driven by Growing Need for Novel Targeted TherapiesThe metastatic melanoma therapeutics market has witnessed significant growth in recent years owing to the rising demand for effective melanoma treatment options. Some key classes of therapeutics available for metastatic melanoma treatment include targeted therapies, immunotherapy, and chemotherapy. Targeted therapies have gained extensive popularity among healthcare professionals as they...0 Yorumlar 0 hisse senetleri 912 Views 0 önizleme
- Metastatic Melanoma Therapeutics: Advances in Treatment Options for Metastatic MelanomaWhile ipilimumab was an important first approval, it only helped about 15-20% of patients and many experienced severe side effects. Since then, several other immunotherapies have been approved that have higher response rates and are generally better tolerated. Keytruda (pembrolizumab) was approved in 2014 for metastatic melanoma patients whose cancer had stopped responding to other treatments....0 Yorumlar 0 hisse senetleri 348 Views 0 önizleme